JZJiahuan Zou

Jiahuan Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiahuan Zou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chenliang Zhang

    Laboratory of Molecular Targeted Therapy in Oncology West China Hospital Sichuan University Chengdu China

    1 shared publication
  • Feng Bi

    Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Gongmin Zhu

    Department of Abdominal Oncology Cancer Center West China Hospital Sichuan University Chengdu China

    1 shared publication
  • Hongwei Xia

    Department of Abdominal Oncology Cancer Center West China Hospital Sichuan University Chengdu China

    1 shared publication
  • Huanji Xu

    Department of Abdominal Oncology Cancer Center West China Hospital Sichuan University Chengdu China

    1 shared publication
  • Huanji Xu

    Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China

    1 shared publication

Latest Publications

  • Open Access

    Casp8 acts through A20 to inhibit PD‐L1 expression: The mechanism and its implication in immunotherapy

    by Jiahuan Zou, Hongwei Xia, Chenliang Zhang, Huanji Xu, Qiulin Tang, Gongmin Zhu, Jielang Li, Feng Bi

    Immunotherapy targeting the PD‐L1/PD‐1 pathway is a novel type of clinical cancer treatment, but only small subsets of patients can benefit from it because of multiple factors. PD‐L1/PD‐1 expression is a biomarker for predicting the efficacy of anti‐PD‐L1/PD‐1 therapy, which highlights the importance of understanding the regulatory mechanisms of PD‐L1 expression in cancer cells. Casp8 is an apical caspase protease involved in mediating cell apoptosis, but it also has multiple nonapoptotic functions. Casp8 mutations are associated with increased risks of cancer, and low expression of Casp8 is closely connected with poor prognosis in patients with cancer. In addition, mutations of Casp8 in lymphocytes also lead to human immunodeficiency, thereby causing dysfunction of the innate immune system, but the roles of Casp8 in antitumor immunity remain unclear. Here, we found that knocking down Casp8 in mouse melanoma cells promoted tumor progression in an immune system–dependent manner. Mechanistically, Casp8 induced PD‐L1 degradation by upregulating TNFAIP3 (A20) expression, a ubiquitin‐editing enzyme that results in PD‐L1 ubiquitination. In addition, compared with Casp8fl/fl mice, mice with conditional deletion of Casp8 in natural killer (NK) cells (Ncr1iCre/+Casp8fl/fl mice) showed a decreased frequency of IFN‐γ+ and CD107a+ NK cells but an increased frequency of PD‐1+ and CTLA‐4+ NK cells. Melanoma cells with Casp8 knocked down exhibited sensitivity to anti‐PD‐1 or anti‐CTLA‐4 antibody treatments, particularly in Ncr1iCre/+Casp8fl/fl mice. Together, the results indicate that Casp8 induces PD‐L1 degradation by upregulating A20 expression and that decreased Casp8 expression is a potential biomarker for predicting the sensitivity to anti‐PD‐L1/PD‐1 immunotherapy.


  • Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study

    by Jielang Li, Huanji Xu, Jiahuan Zou, Xin Wang, Zhiping Li, Yali Shen

    Mitomycin (MMC)/5-fluoroural (5-FU) with concurrent radiation is the standard treatment of anal squamous cell carcinoma (ASCC). The aim of this study is to evaluate the efficacy and safety of cisplatin/capecitabine (XP) as an alternative with intensity-modulated radiation therapy (IMRT) in ASCC setting. We retrospectively screened all patients with stage I–IV ASCC from January 2010 to June 2019. The records of patients who received definitive chemoradiation with cisplatin/capecitabine (XP) and IMRT were collected and analyzed. The first patient was treated with XP in 2017, so totally 11 patients were included in our study from January 2017 to June 2019. All patients have experienced clinical complete response (cCR). After a median follow-up of 30 months (range, 18–39 months), no patient had local recurrence or distant metastasis. Two-year colostomy-free survival (CFS) and two-year disease-free survival (DFS) were both 100%. The median overall survival (OS) has not reached. Grade 3 acute toxicities included leukopenia (1, 9.1%), neutropenia (2, 18.2%) and thrombocytopenia (2, 18.2%). No grade 4 acute adverse events occurred. In our study, cisplatin/capecitabine combined with IMRT was safe in ASCC patients, with favorable efficacy as an alternative, and is expected to be explored in study with larger sample.